We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+3.95%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$269M
AUM Growth
+$2.58M
Cap. Flow
-$7.75M
Cap. Flow %
-2.88%
Top 10 Hldgs %
61.2%
Holding
83
New
15
Increased
18
Reduced
11
Closed
33

Top Buys

Rank Stock Value
1
ACRS icon
Aclaris Therapeutics
ACRS
+$9.5M
2
ASMB icon
Assembly Biosciences
ASMB
+$8.21M
3
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$5.14M
4
IRIX icon
IRIDEX
IRIX
+$4.74M
5
ASND icon
Ascendis Pharma A/S
ASND
+$4.24M

Top Sells

Rank Stock Value
1
EVDY
Everyday Health, Inc.
EVDY
+$11.9M
2
AERI
Aerie Pharmaceuticals
AERI
+$8.7M
3
CEMP
Cempra, Inc.
CEMP
+$5.08M
4
INNL
Innocoll Holdings plc Ordinary Shares
INNL
+$3.9M
5
FOLD
Amicus Therapeutics
FOLD
+$3.63M

Sector Composition

Rank Sector Weight
1 Healthcare 77.17%
2 Technology 2.58%
3 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AUPH icon
26
Aurinia Pharmaceuticals
AUPH
$1.87B
$2.1M 0.78%
+1,000,000
New +$3.22M
AERI
27
DELISTED
Aerie Pharmaceuticals
AERI
$1.89M 0.7%
50,000
-230,000
-82% -$8.7M
CLSD
28
DELISTED
Clearside Biomedical
CLSD
$1.56M 0.58%
+11,667
New +$2.93M
ZBH icon
29
Zimmer Biomet
ZBH
$18.8B
$1.55M 0.58%
+15,450
New +$1.66M
SRPT icon
30
PUT
Sarepta Therapeutics
SRPT
$1.68B
$1.37M 0.51%
+50,000
New +$2.01M
EPIX
31
DELISTED
ESSA Pharma
EPIX
$1.33M 0.49%
30,265
+930
+3% +$40.5K
EXEL icon
32
PUT
Exelixis
EXEL
$13.8B
$1.19M 0.44%
+80,000
New +$1.15M
ALIM
33
DELISTED
Alimera Sciences
ALIM
$1.05M 0.39%
64,955
– –
IOVA icon
34
CALL
Iovance Biotherapeutics
IOVA
$1.93B
$1.04M 0.39%
+150,000
New +$1.03M
BCRX icon
35
BioCryst Pharmaceuticals
BCRX
$2.24B
$950K 0.35%
150,000
-404,448
-73% -$2.1M
RMTI icon
36
PUT
Rockwell Medical
RMTI
$28.5M
$917K 0.34%
+1,273
New +$880K
FOLD
37
DELISTED
Amicus Therapeutics
FOLD
$722K 0.27%
145,300
-524,700
-78% -$3.63M
SPNC
38
DELISTED
Spectranetics Corp
SPNC
$674K 0.25%
+27,500
New +$647K
BCRX icon
39
CALL
BioCryst Pharmaceuticals
BCRX
$2.24B
$627K 0.23%
99,000
-8,200
-8% -$42.7K
ARDX icon
40
Ardelyx
ARDX
$1.23B
$382K 0.14%
26,891
+815
+3% +$11.6K
IMMU
41
CALL
DELISTED
Immunomedics Inc
IMMU
$367K 0.14%
100,000
+41,400
+71% +$122K
ASMB icon
42
CALL
Assembly Biosciences
ASMB
$503M
$122K 0.05%
+833
New +$124K
OTLK icon
43
Outlook Therapeutics
OTLK
$171M
$88K 0.03%
182
-1,352
-88% -$757K
ONSIZ
44
DELISTED
Oncobiologics, Inc. Series B Warrant
ONSIZ
$76K 0.03%
96,833
– –
MNKD icon
45
PUT
MannKind Corp
MNKD
$1.17B
$58K 0.02%
18,000
– –
PLUR icon
46
PUT
Pluri
PLUR
$17M
$30K 0.01%
+264
New +$32.1K
ONSIW
47
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
$18K 0.01%
96,833
– –
NBSE
48
CALL
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$15K 0.01%
+25
New +$26.4K
ACAD icon
49
CALL
Acadia Pharmaceuticals
ACAD
$4.39B
– –
-40,000
Closed -$1.27M
AGEN
50
Agenus
AGEN
$326M
– –
-5,308
Closed -$748K
1
2
3 4

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q4 2016 Portfolio in Review

As of Q4 2016, Acuta Capital Partners held 83 positions worth $269M, up 0.97% from $266M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Acuta Capital Partners's Q4 2016 filing shows 15 new, 18 increased, 11 reduced and 33 closed positions. Its largest new stake was Aclaris Therapeutics: 372,753 shares worth $10.1M. The largest sale was Everyday Health, Inc., an estimated $11.9M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 68% a quarter earlier, followed by Technology and Industrials.

  • Acuta Capital Partners's largest Q4 2016 buy was Aclaris Therapeutics: 372,753 shares worth $10.1M.
  • Acuta Capital Partners added most to Assembly Biosciences in Q4 2016, an estimated $8.21M increase.
  • Acuta Capital Partners's biggest Q4 2016 reduction was Aerie Pharmaceuticals, cutting an estimated $8.7M.
  • Acuta Capital Partners fully exited Everyday Health, Inc. in Q4 2016, selling an estimated $11.9M.
  • Acuta Capital Partners's ten largest holdings make up 61% of its $269M portfolio in Q4 2016.
  • Acuta Capital Partners opened 15 new positions and closed 33 in Q4 2016.
  • Acuta Capital Partners's portfolio value rose 0.97% quarter-over-quarter to $269M.

Based on Acuta Capital Partners's 13F filing for Q4 2016, filed 13 Feb 2017.